SCHOTT Pharma Invests Over €100M to Expand RTU Cartridge Production in Hungary

• SCHOTT Pharma is investing more than €100 million in its Lukácsháza, Hungary site to expand sterile ready-to-use (RTU) cartridge production.

• The expansion will support increased demand for drug containment solutions used in therapies for diabetes, obesity, and immunological diseases.

SCHOTT Pharma, a provider of drug containment and delivery systems, has announced a more than €100 million investment to expand its manufacturing capabilities in Lukácsháza, Hungary. The move aims to boost production of sterile ready-to-use (RTU) cartridges in response to rising global demand.

The company has broken ground on a new high-value solutions (HVS) facility at the site, marking the second major project in Lukácsháza following the June 2024 opening of a prefillable glass syringe production unit. The expansion is expected to create over 100 new jobs and enhance SCHOTT Pharma’s capacity to supply containment solutions for therapies such as GLP-1 drugs, insulin, and hormone-based treatments.

According to Andreas Reisse, CEO of SCHOTT Pharma, “To meet growing demand, we are expanding our capabilities and presence in the diabetes and obesity fields. That is why we are investing more than 100 million euros in our plant in Hungary.”

The Lukácsháza site will become SCHOTT Pharma’s second location, after St. Gallen in Switzerland, to produce sterile cartridges. The new facility will incorporate advanced technologies, including a new washing line and steam sterilisation system designed to reduce environmental impact. Operations will be fully integrated and automated to ensure high-quality, sterile output.

The project has received support from the Hungarian Ministry of Foreign Affairs and Trade. As stated by Eva Szabó, Site Manager, Lukácsháza remains central to SCHOTT Pharma’s global growth strategy and regional supply capabilities.